Edition:
United Kingdom

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.85USD
18 Sep 2018
Change (% chg)

$0.05 (+1.32%)
Prev Close
$3.80
Open
$3.80
Day's High
$3.90
Day's Low
$3.80
Volume
14,625
Avg. Vol
29,244
52-wk High
$5.00
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Compugen's Q2 Loss Per Share $0.19
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.19.  Full Article

Compugen Announces FDA Clearance Of IND Application For COM701, A First-In-Class Immuno-Oncology Therapeutic Antibody
Monday, 2 Jul 2018 

July 2 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COM701, A FIRST-IN-CLASS IMMUNO-ONCOLOGY THERAPEUTIC ANTIBODY.  Full Article

Compugen Reports Q1 Revenue Of $10 Million
Wednesday, 9 May 2018 

May 9 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FIRST QUARTER 2018 RESULTS.Q1 EARNINGS PER SHARE $0.00.Q1 REVENUE $10 MILLION.  Full Article

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)